In a phase IIa trial including individuals with hepatic steatosis and fibrosis, treatment for 12 weeks with a FAS inhibitor, TVB-2640, dose-dependently decreased circulating ALT, AST and liver fat determined by MRI-PDFF. This evidence concerns the gene GPT and fatty liver disease.